Karuna Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Karuna Therapeutics

04/05/2023 14:33

* Karuna Therapeutics Inc  KRTX.OQ  reported a quarterly
adjusted
loss of $2.80​​ per share for the quarter ended in March. The
mean expectation of seventeen analysts for the quarter was for a
loss of $2.76 per share.
    * Revenue was $654.00 thousand​; analysts expected zero. 
    * Karuna Therapeutics Inc's reported EPS for the quarter was
a
loss of $2.80​.
    * The mean earnings estimate of analysts had fallen by
about 10.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Karuna Therapeutics Inc shares had risen by 15.8% this
quarter and gained 7.1% so far this year.
    * The company reported a quarterly loss of $97.57 million.
    * Wall Street's median 12-month price target for Karuna
Therapeutics Inc is $275.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 19 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 01:33 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -2.76          -2.80          Missed
 Dec. 31 2022      -2.25          -2.22          Beat
 Sep. 30 2022      -2.13          -2.38          Missed
 Jun. 30 2022      -2.09          -2.17          Missed